By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly injecting an immune-activating compound into prostate tumors before surgery ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...

Prostate cancer is one of the most common forms of cancer among men, but advancements in medical science have made it more treatable than ever before. Prostate cancer surgery is a crucial step in the ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...